Biotechnology The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund), UK pharma major AstraZeneca and Unicorn Capital Partners, a biotech-specialized VC fund, based in Moscow, today announced the agreement to invest in Target Medicals, developing an inhibitor of aldosterone synthase, a key enzyme responsible for production of aldosterone. 1 February 2022